Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
Nat Med
    April 2024
  1. SCHULER M, Cuppens K, Plones T, Wiesweg M, et al
    Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial.
    Nat Med. 2024 Apr 30. doi: 10.1038/s41591-024-02965.
    >> Share

  2. TAMMEMAGI MC, Darling GE, Schmidt H, Walker MJ, et al
    Risk-based lung cancer screening performance in a universal healthcare setting.
    Nat Med. 2024;30:1054-1064.
    >> Share

  3. VAIDYA A, Chen RJ, Williamson DFK, Song AH, et al
    Demographic bias in misdiagnosis by computational pathology models.
    Nat Med. 2024;30:1174-1190.
    >> Share

  4. SINGHAL A, Li BT, O'Reilly EM
    Targeting KRAS in cancer.
    Nat Med. 2024;30:969-983.
    >> Share

  5. GHILARDI G, Fraietta JA, Gerson JN, Van Deerlin VM, et al
    T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
    Nat Med. 2024;30:984-989.
    >> Share

    February 2024
  6. BESSE B, Pons-Tostivint E, Park K, Hartl S, et al
    Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
    Nat Med. 2024 Feb 13. doi: 10.1038/s41591-024-02808.
    >> Share

    October 2023
  7. DEUTSCH JS, Cimino-Mathews A, Thompson E, Provencio M, et al
    Association between pathologic response and survival after neoadjuvant therapy in lung cancer.
    Nat Med. 2023 Oct 30. doi: 10.1038/s41591-023-02660.
    >> Share

  8. CHAFT JE, Oezkan F, Kris MG, Bunn PA, et al
    Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
    Nat Med. 2023 Oct 10. doi: 10.1038/s41591-023-02627.
    >> Share

  9. ANAGNOSTOU V, Ho C, Nicholas G, Juergens RA, et al
    ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.
    Nat Med. 2023 Oct 9. doi: 10.1038/s41591-023-02598.
    >> Share

    September 2023
  10. CHO BC, Kim DW, Spira AI, Gomez JE, et al
    Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.
    Nat Med. 2023 Sep 14. doi: 10.1038/s41591-023-02554.
    >> Share

    July 2023
  11. LIU SM, Tu HY, Wei XW, Yan HH, et al
    First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.
    Nat Med. 2023 Jul 24. doi: 10.1038/s41591-023-02461.
    >> Share

  12. GUTIERREZ M, Lam WS, Hellmann MD, Gubens MA, et al
    Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.
    Nat Med. 2023 Jul 10. doi: 10.1038/s41591-023-02385.
    >> Share

    June 2023
  13. SIKKEMA L, Ramirez-Suastegui C, Strobl DC, Gillett TE, et al
    An integrated cell atlas of the lung in health and disease.
    Nat Med. 2023;29:1563-1577.
    >> Share

    May 2023
  14. GOLDSMITH KC, Park JR, Kayser K, Malvar J, et al
    Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
    Nat Med. 2023;29:1092-1102.
    >> Share

    April 2023
  15. AL-SAWAF O, Weiss J, Skrzypski M, Lam JM, et al
    Body composition and lung cancer-associated cachexia in TRACERx.
    Nat Med. 2023 Apr 12. doi: 10.1038/s41591-023-02232.
    >> Share


  16. High-resolution circulating tumor DNA testing predicts survival in metastatic lung cancer clinical trials.
    Nat Med. 2023;29:797-798.
    >> Share


  17. Clinicogenomic landscape of morphological evolution in lung adenocarcinoma.
    Nat Med. 2023;29:795-796.
    >> Share

  18. KARASAKI T, Moore DA, Veeriah S, Naceur-Lombardelli C, et al
    Evolutionary characterization of lung adenocarcinoma morphology in TRACERx.
    Nat Med. 2023;29:833-845.
    >> Share

  19. GLITZA OLIVA IC, Ferguson SD, Bassett R Jr, Foster AP, et al
    Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.
    Nat Med. 2023;29:898-905.
    >> Share

    March 2023
  20. CONROY M, Forde PM
    Advancing neoadjuvant immunotherapy for lung cancer.
    Nat Med. 2023 Mar 16. doi: 10.1038/s41591-023-02246.
    >> Share

  21. CASCONE T, Leung CH, Weissferdt A, Pataer A, et al
    Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
    Nat Med. 2023 Mar 16. doi: 10.1038/s41591-022-02189.
    >> Share

  22. ASSAF ZJF, Zou W, Fine AD, Socinski MA, et al
    A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer.
    Nat Med. 2023 Mar 16. doi: 10.1038/s41591-023-02226.
    >> Share

    February 2023
  23. NIKNAFS N, Balan A, Cherry C, Hummelink K, et al
    Persistent mutation burden drives sustained anti-tumor immune responses.
    Nat Med. 2023;29:440-449.
    >> Share

    November 2022
  24. JEE J, Lebow ES, Yeh R, Das JP, et al
    Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.
    Nat Med. 2022;28:2353-2363.
    >> Share

    October 2022
  25. BAJAJ SS, Pan M, Potter AL, Yang CJ, et al
    Cigarette package labels to promote lung cancer screening.
    Nat Med. 2022 Oct 13. pii: 10.1038/s41591-022-02042.
    >> Share

    September 2022
  26. CHAFT JE, Oezkan F, Kris MG, Bunn PA, et al
    Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
    Nat Med. 2022 Sep 12. pii: 10.1038/s41591-022-01962.
    >> Share

  27. PETERS S, Dziadziuszko R, Morabito A, Felip E, et al
    Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
    Nat Med. 2022;28:1831-1839.
    >> Share

    August 2022
  28. GOGISHVILI M, Melkadze T, Makharadze T, Giorgadze D, et al
    Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.
    Nat Med. 2022 Aug 25. pii: 10.1038/s41591-022-01977.
    >> Share

    April 2022
  29. O'LEARY K
    New treatment option for early-stage lung cancer.
    Nat Med. 2022 Apr 25. pii: 10.1038/d41591-022-00055.
    >> Share

  30. KIM ES, Velcheti V, Mekhail T, Yun C, et al
    Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.
    Nat Med. 2022 Apr 14. pii: 10.1038/s41591-022-01754.
    >> Share

    February 2022
  31. DEROSA L, Routy B, Thomas AM, Iebba V, et al
    Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer.
    Nat Med. 2022 Feb 3. pii: 10.1038/s41591-021-01655.
    >> Share

    November 2021
  32. FORDE PM, Anagnostou V, Sun Z, Dahlberg SE, et al
    Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
    Nat Med. 2021;27:1910-1920.
    >> Share

    August 2021
  33. CREELAN BC, Wang C, Teer JK, Toloza EM, et al
    Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.
    Nat Med. 2021 Aug 12. pii: 10.1038/s41591-021-01462.
    >> Share

  34. VEATCH JR, Simon S, Riddell SR
    Tumor-infiltrating lymphocytes make inroads in non-small-cell lung cancer.
    Nat Med. 2021 Aug 12. pii: 10.1038/s41591-021-01445.
    >> Share

  35. WANG M, Herbst RS, Boshoff C
    Toward personalized treatment approaches for non-small-cell lung cancer.
    Nat Med. 2021 Aug 12. pii: 10.1038/s41591-021-01450.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016